U.S. Markets closed

NGM Biopharmaceuticals, Inc. (NGM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.13+0.02 (+0.10%)
At close: 4:00PM EDT

19.13 0.00 (0.00%)
After hours: 4:28PM EDT

NGM Biopharmaceuticals, Inc.

333 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 243 5555

Full Time Employees186

Key Executives

NameTitlePayExercisedYear Born
Mr. William J. Rieflin J.D.Exec. Chairman of DirectorsN/AN/A1960
Dr. David J. WoodhouseCEO & Director615.75kN/A1971
Dr. Jin-Long ChenFounder, Chief Scientific Officer & Director625.75kN/A1963
Dr. Aetna Wun TrombleyConsultant550.75kN/A1980
Ms. Siobhan Nolan ManginiCFO and Principal Financial & Accounting OfficerN/AN/A1981
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Corporate Governance

NGM Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.